Novartis Intends To Defend Validity Of Gilenya Dosing Regimen Patent

(RTTNews) – Novartis (NVS) said Tuesday that the U.S. Court of Appeals for the Federal Circuit or CAFC issued a new, negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for Gilenya.

This post was originally published on this site